ENDCOVID

Inspiration

Came from our clinical background

What it does

It blocks the inflammatory response in COVID-19 pneumonia

How we built it

Based on our pre-clinical data and clinical expertise

Challenges we ran into

Repurposing an existing drug is not as easy as it seems, even in the middle of COVID-19 medical crisis

Accomplishments that we're proud of

Our phase 2 clinical study has received encouraging comments by the Italian drug regulatory authority

What we learned

Collaborating among different medical specialties

What's next for ENDCOVID

Completion of a phase 2 clinical study to make the treatment available to every COVID-19 patient!